

REPOS THERAPEUTICS INC.
Form 8-K
September 18, 2006

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): 09/18/2006

Repos Therapeutics Inc.

(Exact name of registrant as specified in its charter)

Commission File Number: 001-15281

Delaware
(State or other jurisdiction of
incorporation)

76-0233274
(IRS Employer
Identification No.)

2408 Timberloch Place, Suite B-7
The Woodlands, Texas 77380
(Address of principal executive offices, including zip code)

(281) 719-3400
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Edgar Filing: REPROS THERAPEUTICS INC. - Form 8-K

Information to be included in the report

Item 8.01. Other Events

Repros Therapeutics Inc. announced today that the Form S-3 shelf registration statement it filed on September 5, 2006 with the Securities and Exchange Commission for up to 5,000,000 shares of common stock was declared effective as of September 15, 2006 and will remain effective for three years.

A copy of the Company's press release is attached hereto as Exhibit 99.1. The press release is incorporated by reference herein and the foregoing description of the press release is qualified in its entirety by reference to the attached exhibit.

Item 9.01. Financial Statements and Exhibits

c. Exhibits

Exhibit

Number	Description
99.1	Press Release dated September 18, 2006.

Signature(s)

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Repros Therapeutics Inc.

Date: September 18, 2006

By: /s/ Louis Ploth, Jr.

Louis Ploth, Jr.
Vice President, Business Development and Chief Financial Officer

Exhibit Index

<u>Exhibit No.</u>	<u>Description</u>
EX-99.1	Press Release dated September 18, 2006.